NASDAQ:APLT

Applied Therapeutics - APLT Stock Forecast, Price & News

$0.90

+0.01 (+0.78%)

(As of 11/25/2022 08:57 PM ET)

Add

Compare

Today's Range: $0.84
▼
$0.95
50-Day Range: $0.54
▼
$1.17
52-Week Range: $0.50
▼
$11.87

Volume: 286,400 shs
Average Volume: 373,007 shs
Market Capitalization: $43.10 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $14.05

Applied Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 1,132.0% Upside
$11.05 Price Target
Short Interest: Healthy
0.48% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.88
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Acquiring Shares
$52,340 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($2.34) to ($1.25) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.75 out of 5 stars

Medical Sector

58th out of 1,044 stocks

Pharmaceutical Preparations Industry

25th out of 510 stocks

3.3

Analyst's Opinion

Consensus Rating
Applied Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.05, Applied Therapeutics has a forecasted upside of 1,132.0% from its current price of $0.90.
Amount of Analyst Coverage
Applied Therapeutics has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.48% of the outstanding shares of Applied Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Applied Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Applied Therapeutics has recently decreased by 10.98%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Applied Therapeutics does not currently pay a dividend.
Dividend Growth
Applied Therapeutics does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Applied Therapeutics has received a 74.24% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Applied Therapeutics is -0.88.

2.7

News and Social Media Coverage

News Sentiment
Applied Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Applied Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 12 people have searched for APLT on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Applied Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Applied Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $52,340.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
17.00% of the stock of Applied Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
83.74% of the stock of Applied Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Applied Therapeutics are expected to grow in the coming year, from ($2.34) to ($1.25) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Applied Therapeutics is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Applied Therapeutics is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Applied Therapeutics has a P/B Ratio of 4.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Applied Therapeutics (NASDAQ:APLT) Stock

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Receive APLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Applied Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

APLT Stock News Headlines

November 9, 2022 | finance.yahoo.com

Applied Therapeutics Reports Third Quarter 2022 Financial Results

October 31, 2022 | finance.yahoo.com

Applied Therapeutics Announces Multiple Data Presentations at the American Heart Association Scientific Sessions November 5-7, 2022

October 25, 2022 | finance.yahoo.com

Applied Therapeutics Announces Full Enrollment in the Registrational Phase 3 ARISE-HF Trial of AT-001 in Diabetic Cardiomyopathy

October 9, 2022 | finance.yahoo.com

Insiders who purchased Applied Therapeutics, Inc. (NASDAQ:APLT) earlier this year lose an additional US$86k as the stock sinks to US$0.62

October 6, 2022 | marketwatch.com

Applied Therapeutics Down 33% on Clinical Trial Update

October 6, 2022 | finance.yahoo.com

Applied Therapeutics' Lead Candidate Pediatric Study Failed To Reach Statistical Significance

October 6, 2022 | markets.businessinsider.com

Applied Therapeutics: AT-007 Trial Shows Positive Data Trend; Yet To Reach Statistical Significance

October 6, 2022 | finance.yahoo.com

Applied Therapeutics Announces Positive Data Trend in AT-007 ACTION-Galactosemia Kids Pediatric Trial; Trial Will Continue to 18 Months in Blinded Format

September 2, 2022 | finance.yahoo.com

Bears are Losing Control Over Applied Therapeutics Inc. (APLT), Here's Why It's a 'Buy' Now

August 16, 2022 | nasdaq.com

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

August 12, 2022 | msn.com

Recap: Applied Therapeutics Q2 Earnings

August 12, 2022 | finance.yahoo.com

Applied Therapeutics Reports Second Quarter 2022 Financial Results

July 28, 2022 | finance.yahoo.com

Applied Therapeutics to Sponsor and Present at the 2022 Galactosemia Foundation Conference

June 23, 2022 | markets.businessinsider.com

Nasdaq Jumps Over 100 Points; Applied Therapeutics Shares Plummet

June 23, 2022 | seekingalpha.com

Applied therapeutics stock sinks on pricing $30M equity offering

June 22, 2022 | finance.yahoo.com

Applied Therapeutics, Inc. Announces Pricing of $30 Million Public Offering of Common Stock and Warrants

June 22, 2022 | marketwatch.com

Applied Therapeutics Shares Dive 33% on Public Offering

June 22, 2022 | seekingalpha.com

Applied Therapeutics launches stock offering

June 22, 2022 | finance.yahoo.com

Applied Therapeutics, Inc. Announces Public Offering of Common Stock and Warrants

June 3, 2022 | marketwatch.com

Applied Therapeutics Up After EMA Orphan Medicinal Product Designation

June 3, 2022 | seekingalpha.com

Applied Therapeutics stock rises on orphan drug status in EU for AT-007 for metabolic disorder

June 3, 2022 | finance.yahoo.com

Applied Therapeutics Receives Orphan Medicinal Product Designation from the EMA for AT-007 for Treatment of Galactosemia

May 14, 2022 | seekingalpha.com

Applied Therapeutics GAAP EPS of -$0.88

May 13, 2022 | finance.yahoo.com

The Zacks Analyst Blog Highlights Angion Biomedica, Applied Therapeutics, Bolt Biotherapeutics, Ikena Oncology, and Landos Biopharma

May 13, 2022 | finance.yahoo.com

Editas' (EDIT) EDIT-301 Gets Orphan Drug Tag for Beta Thalassemia

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive APLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Applied Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

APLT Company Calendar

Last Earnings: 11/12/2021
Today: 11/27/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 3/09/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:APLT
CUSIP: N/A
CIK: 1697532
Web: www.appliedtherapeutics.com
Phone: (212) 220-9226
Fax: N/A
Employees: 34
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $11.05
High Stock Price Forecast: $23.00
Low Stock Price Forecast: $2.25
Forecasted Upside/Downside: +1,466.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.28)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-105,580,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -259.77%
Return on Assets: -125.48%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.19
Quick Ratio: 1.19

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.20 per share
Price / Book: 4.48

Miscellaneous

Outstanding Shares: 48,059,000
Free Float: 39,889,000
Market Cap: $43.10 million
Optionable: Not Optionable
Beta: 1.53

Key Executives

Dr. Shoshana Shendelman Ph.D. (Age 43)
Chair of the Board of Directors, Founder, Pres, CEO & Sec.
Comp: $588.47k

Dr. Riccardo Perfetti M.D. (Age 62)
Ph.D., Chief Medical Officer
Comp: $792.25k

Mr. Chids Mahadevan (Age 52)
Sr. VP of Fin. & Interim Principal Financial Officer

Mr. Steven Ortega (Age 36)
Chief Accounting Officer

Mr. Adam Hansard (Age 46)
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

APLT Stock - Frequently Asked Questions

Should I buy or sell Applied Therapeutics stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Applied Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" APLT shares.
View APLT analyst ratings or view top-rated stocks.
What is Applied Therapeutics' stock price forecast for 2023?: 2 brokers have issued 1 year price targets for Applied Therapeutics' shares. Their APLT share price forecasts range from $2.25 to $23.00. On average, they expect the company's stock price to reach $11.05 in the next twelve months. This suggests a possible upside of 1,131.9% from the stock's current price.
View analysts price targets for APLT or view top-rated stocks among Wall Street analysts.
How have APLT shares performed in 2022?: Applied Therapeutics' stock was trading at $8.95 at the beginning of the year. Since then, APLT shares have decreased by 90.0% and is now trading at $0.8970.
View the best growth stocks for 2022 here.
When is Applied Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our APLT earnings forecast.
How were Applied Therapeutics' earnings last quarter?: Applied Therapeutics, Inc. (NASDAQ:APLT) issued its quarterly earnings results on Friday, November, 12th. The company reported ($1.09) earnings per share for the quarter, beating the consensus estimate of ($1.15) by $0.06.
What other stocks do shareholders of Applied Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Therapeutics investors own include Enterprise Products Partners (EPD), Pfizer (PFE), Advanced Micro Devices (AMD), Energy Transfer (ET), Micron Technology (MU), NVIDIA (NVDA), Verizon Communications (VZ), AbbVie (ABBV), Walt Disney (DIS) and Raytheon Technologies (RTX).

When did Applied Therapeutics IPO?: (APLT) raised $60 million in an initial public offering on the week of May 13th 2019. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and UBS Investment Bank served as the underwriters for the IPO and Baird was co-manager.
What is Applied Therapeutics' stock symbol?: Applied Therapeutics trades on the NASDAQ under the ticker symbol "APLT."
Who are Applied Therapeutics' major shareholders?: Applied Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Point72 Asset Management L.P. (3.58%), BlackRock Inc. (1.10%), Vanguard Group Inc. (0.94%), Renaissance Technologies LLC (0.70%), Two Sigma Advisers LP (0.52%) and Ergoteles LLC (0.11%). Insiders that own company stock include Charles Silberstein, Chids Mahadevan, Joel S Marcus, Leslie D Funtleyder, Real Estate Equitie Alexandria, Riccardo Perfetti, Shoshana Shendelman and Stacy J Kanter.
View institutional ownership trends.
How do I buy shares of Applied Therapeutics?: Shares of APLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Applied Therapeutics' stock price today?: One share of APLT stock can currently be purchased for approximately $0.90.
How much money does Applied Therapeutics make?: Applied Therapeutics (NASDAQ:APLT) has a market capitalization of $43.11 million. The company earns $-105,580,000.00 in net income (profit) each year or ($3.28) on an earnings per share basis.
How can I contact Applied Therapeutics?: Applied Therapeutics' mailing address is 340 MADISON AVENUE 19TH FLOOR, NEW YORK NY, 10173. The official website for the company is www.appliedtherapeutics.com. The company can be reached via phone at (212) 220-9226 or via email at maeve@argotpartners.com.

This page (NASDAQ:APLT) was last updated on 11/28/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Applied Therapeutics - APLT Stock Forecast, Price & News

Applied Therapeutics MarketRank™ Forecast

Overall MarketRank™